These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

227 related items for PubMed ID: 19383734

  • 21. Long-Term Sirolimus for Primary Immunosuppression in Heart Transplant Recipients.
    Asleh R, Briasoulis A, Kremers WK, Adigun R, Boilson BA, Pereira NL, Edwards BS, Clavell AL, Schirger JA, Rodeheffer RJ, Frantz RP, Joyce LD, Maltais S, Stulak JM, Daly RC, Tilford J, Choi WG, Lerman A, Kushwaha SS.
    J Am Coll Cardiol; 2018 Feb 13; 71(6):636-650. PubMed ID: 29420960
    [Abstract] [Full Text] [Related]

  • 22. Hypercholesterolemia after conversion to sirolimus as primary immunosuppression and cardiac allograft vasculopathy in heart transplant recipients.
    Asleh R, Briasoulis A, Pereira NL, Edwards BS, Frantz RP, Daly RC, Lerman A, Kushwaha SS.
    J Heart Lung Transplant; 2018 Nov 13; 37(11):1372-1380. PubMed ID: 30174165
    [Abstract] [Full Text] [Related]

  • 23. Coronary flow reserve measurement detects transplant coronary artery disease in pediatric heart transplant patients.
    Schubert S, Abdul-Khaliq H, Wellnhofer E, Hiemann NE, Ewert P, Lehmkuhl HB, Meyer R, Miera O, Peters B, Hetzer R, Berger F.
    J Heart Lung Transplant; 2008 May 13; 27(5):514-21. PubMed ID: 18442717
    [Abstract] [Full Text] [Related]

  • 24. Absence of proteinuria predicts improvement in renal function after conversion to sirolimus-based immunosuppressive regimens in lung transplant survivors with chronic kidney disease.
    Stephany BR, Boumitri M, Budev M, Alao B, Poggio ED.
    J Heart Lung Transplant; 2009 Jun 13; 28(6):564-71. PubMed ID: 19481016
    [Abstract] [Full Text] [Related]

  • 25. [Effects of acute rejection on the endothelium-dependent relaxation of coronary arteries of the transplanted heart in dogs].
    Bouchard D, Cartier R, Despatis MA, Carrier M, Leung TK.
    Ann Chir; 1995 Jun 13; 49(8):735-42. PubMed ID: 8561429
    [Abstract] [Full Text] [Related]

  • 26. Correlation between circulating endothelial progenitor cell function and allograft rejection in heart transplant patients.
    Sathya CJ, Sheshgiri R, Prodger J, Tumiati L, Delgado D, Ross HJ, Rao V.
    Transpl Int; 2010 Jun 13; 23(6):641-8. PubMed ID: 20102553
    [Abstract] [Full Text] [Related]

  • 27. Myocardial ischaemia in patients with coronary endothelial dysfunction: insights from body surface ECG mapping and implications for invasive evaluation of chronic chest pain.
    Summers MR, Lerman A, Lennon RJ, Rihal CS, Prasad A.
    Eur Heart J; 2011 Nov 13; 32(22):2758-65. PubMed ID: 21733912
    [Abstract] [Full Text] [Related]

  • 28. Impact of paraoxonase polymorphism (Q192R) on endothelial function in intact coronary circulation.
    Yamane T, Matsumoto T, Nakae I, Takashima H, Tarutani Y, Tamaki S, Horie M.
    Hypertens Res; 2006 Jun 13; 29(6):417-22. PubMed ID: 16940704
    [Abstract] [Full Text] [Related]

  • 29. Factors associated with proteinuria in renal transplant recipients treated with sirolimus.
    Liew A, Chiang GS, Vathsala A.
    Transpl Int; 2009 Mar 13; 22(3):313-22. PubMed ID: 19054382
    [Abstract] [Full Text] [Related]

  • 30. Soluble interleukin-2-receptor levels as a marker of coronary microvascular dysfunction after heart transplantation.
    Weis M, Hartmann A, Scheuermann EH, Olbrich HG.
    J Heart Lung Transplant; 1998 Mar 13; 17(3):294-8. PubMed ID: 9563606
    [Abstract] [Full Text] [Related]

  • 31. Coronary endothelial dysfunction is not rapidly reversible with ascorbic acid.
    Widlansky ME, Biegelsen ES, Hamburg NM, Duffy SJ, Keaney JF, Vita JA.
    Free Radic Biol Med; 2004 Jan 01; 36(1):123-30. PubMed ID: 14732296
    [Abstract] [Full Text] [Related]

  • 32. Three-year health-related quality-of-life outcomes for sirolimus-treated kidney transplant patients after elimination of cyclosporine.
    Russ G, Jamieson N, Oberbauer R, Arias M, Murgia MG, Blancho G, Sato R, Stoeckl M, Revicki DA.
    Transpl Int; 2007 Oct 01; 20(10):875-83. PubMed ID: 17854445
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Impact on renal function of the use of sirolimus in cardiac transplantation.
    Ubilla M, Mastrobuoni S, Cordero A, Castaño S, Herreros J, Rábago G.
    Transplant Proc; 2007 Sep 01; 39(7):2401-2. PubMed ID: 17889202
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Sirolimus as primary immunosuppression attenuates allograft vasculopathy with improved late survival and decreased cardiac events after cardiac transplantation.
    Topilsky Y, Hasin T, Raichlin E, Boilson BA, Schirger JA, Pereira NL, Edwards BS, Clavell AL, Rodeheffer RJ, Frantz RP, Maltais S, Park SJ, Daly RC, Lerman A, Kushwaha SS.
    Circulation; 2012 Feb 07; 125(5):708-20. PubMed ID: 22207715
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Proliferation signal inhibitors and cardiac allograft vasculopathy.
    Raichlin E, Kushwaha SS.
    Curr Opin Organ Transplant; 2008 Oct 07; 13(5):543-50. PubMed ID: 19060540
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.